Issue Date: September 4, 2017
A path to the brain’s secrets
The brain has an earned reputation as a drug development graveyard. Because researchers lacked both a solid understanding of the root causes of neurological disease and good tools to track disease progression or drug effectiveness, our most complex organ long stymied pharmaceutical companies. Over the past decade, many large pharmaceutical makers significantly pared back neuroscience research, and some exited the space entirely.
Those that stayed haven’t yet been rewarded. . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society